Sai Life Sciences is expanding capacity and moving into peptides and formulations as global pharma companies diversify supply chains beyond China. The company expects stronger H2FY27 revenue and earnings, supported by new capacity, late-stage molecules and long-term FTE contracts.
Sai Life Sciences is expanding capacity and moving into peptides and formulations as global pharma companies diversify supply chains beyond China. The company expects stronger H2FY27 revenue and earnings, supported by new capacity, late-stage molecules and long-term FTE contracts.
<iframe src="https://hindustansphere.com/embed/cluster/5eaf83aa68436b777876878c38915fc8a02e9bc7" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Sai Life Sciences' CRDMO Growth Is Expanding Beyond China-Plus-One"></iframe>
